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Abstract
Background: Retroviruses are widely used to transfer genes to mammalian cells efficiently and
stably. However, genetic elements required for high-level gene expression are incompatible with
standard systems. The retroviral RNA genome is produced by cellular transcription and post-
transcriptional processing within packaging cells: Introns present in the retroviral genomic
transcript are removed by splicing, while polyadenylation signals lead to the production of
ineffective truncated genomes. Furthermore strong enhancer/promoters within the retroviral
payload lead to detrimental competition with the retroviral enhancer/promoter.
Results: By exploiting a new method of producing the retroviral genome in vitro it is possible to
produce infectious retroviral particles carrying a high-level expression cassette that completely
prohibits production of infectious retroviral particles by conventional methods.
We produced an expression cassette comprising a strong enhancer/promoter, an optimised intron,
the GFP open reading frame and a strong polyadenylation signal. This cassette was cloned into both
a conventional MMLV retroviral vector and a vector designed to allow in vitro transcription of the
retroviral genome by T7 RNA polymerase.
When the conventional retroviral vector was transfected into packaging cells, the expression
cassette drove strong GFP expression, but no infectious retrovirus was produced. Introduction of
the in vitro produced uncapped retroviral genomic transcript into the packaging cells did not lead
to any detectable GFP expression. However, infectious retrovirus was easily recovered, and when
used to infect target primary human cells led to very high GFP expression – up to 3.5 times greater
than conventional retroviral LTR-driven expression.
Conclusion: Retroviral vectors carrying an optimized high-level expression cassette do not
produce infectious virions when introduced into packaging cells by transfection of DNA. Infectious
retrovirus carrying the same cassette is readily produced when packaging cells are transfected with
in vitro transcribed retroviral genomic RNA. The applications of this technique are not limited to
producing the higher levels of transgene expression demonstrated here. For example, novel
reporters with alternatively spliced exon-intron configurations could readily be transduced into
virtually any cell. Furthermore, because the in vitro transcripts are not translated within the
packaging cells, retroviruses carrying genes lethal to the packaging cells can also be produced.
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Retroviral vector systems are routinely used as delivery
vehicles for efficient and stable gene transfer into mam-
malian cells [1]. Since their inception more than 20 years
ago, retrovirus vectors have been developed to transfer
various genetic elements for varied purposes: Stable
expression of cDNA for gene studies and therapy; efficient
expression of short hairpin RNA (shRNA) to trigger RNA
interference; integration of splice donor sequences for
gene trapping; generation of gene reporter cell lines [2,3].
In spite of the accommodating nature of the retroviral
genome, there are inherent limitations in the retroviral
life cycle that constrain vector design and impede full uti-
lization of the system [4]. The retroviral genome must be
produced by RNA polymerase II in the nucleus of the
packaging cell, edited (capped and polyadenylated) and
transported to the cytoplasm for assimilation into a
mature virion at the plasma membrane. Hence sequences
that interfere with nuclear export or express products det-
rimental to packaging cell function or survival will not
yield virus. Extraneous post-transcriptional processing sig-
nals present in the vector sequence will produce incom-
plete genomic transcripts (e.g. polyadenylation signal) or
be removed prior to packaging and not transferred (e.g.
introns) [5,6] (Figure 1A–C). Frequently, vectors are
designed with an internal promoter to drive high trans-
gene expression which leads to "promoter interference"
with the retroviral long-terminal repeat (LTR) and severely
compromises viral titer [7,8].
Results and Discussion
In spite of the popularity of retroviral vectors, little has
been done to address these limitations. We recently devel-
oped a simple approach that dramatically expands the
range of genetic elements transferable by retroviral vectors
[9]. The system employs in vitro generated RNA to nucle-
ate retroviral virions, completely circumventing packaging
cell genomic transcription and translation (Figure 1D).
To demonstrate the utility of this innovation, we endeav-
oured to create a high expression retroviral vector using a
known optimal constellation of genetic elements pre-
dicted to be incompatible with current systems. Indeed we
show that a retroviral vector with substantially higher
transgene expression in primary human cells can be con-
structed using the in vitro transcribed retroviral genomic
RNA approach, while the same gene cassette prohibited
the production of virus by the conventional system.
A series of retroviral vectors were constructed to carry a
standard strong GFP expression cassette comprising EGFP
cDNA flanked by an optimized intron, and a potent late
SV40 polyadenylation signal under the control of the
cytomegalovirus immediate early (CMV IE) promoter
[10]. This expression cassette was cloned in both orienta-
tions into a standard retroviral vector (pC) or into a retro-
viral vector designed to allow in vitro transcription of the
retroviral genomic RNA (pT) (Figure 2). pT is similar to
conventional retroviral vectors except that the U3 region
of the 5' LTR has been replaced by the binding site for bac-
teriophage T7 RNA polymerase, positioned so that tran-
scription initiates at the correct nucleotide. The U5 region
of the 3'LTR, which contains the natural polyadenylation
signal, is replaced by 40 A's to mimic a polyA tail followed
by a site for the restriction enzyme MluI to allow lineari-
sation of the vector. As controls, we used the GFP open
reading frame alone (without the additional promoter,
intron or polyadenylation site) cloned into both conven-
tional (pC-GFP) and T7-transcribed (pT-GFP) retroviral
vectors. On integration into the target cell genome, these
vectors are expected to produce essentially identical
sequences.
When transfected into packaging cells, the standard retro-
viral vectors (pC) produced high levels of GFP expression
as measured by flow cytometry (Figure 3A). However, the
presence of the internal CMV-expression cassette com-
pletely abrogated production of infectious virus (Figure
3B). The complete loss of infectious virus in both pC-
cGreen and pC-neerGc is primarily due to the presence of
the strong, bidirectional SV40 polyadenylation site [11].
However, competition between the internal CMV pro-
moter and the 5' LTR CMV promoter is also likely to con-
tribute to the loss of titer [7].
In contrast, in vitro transcription system based vectors (pT)
carrying the same CMV expression cassette readily gener-
ated infectious virus following transfection of in vitro tran-
scribed RNA genomes into packaging cells. The pT vectors
produced no detectable GFP expression in the packaging
cells, due to the lack of requisite translation signals (e.g. 5'
cap) on the RNA transcripts, a notable advantage of the
system (not shown;[1]). Primary human umbilical cord
endothelial cells (HUVEC) were readily infected with viral
supernatants generated by the pT-vectors carrying the
strong GFP expression cassette (pT-cGreen and pT-
neerGc) and expressed markedly higher (up to 3.5-fold)
levels than obtained with the conventional LTR-driven
(pC-GFP, pT-GFP) vectors (Figure 3C). The reverse orien-
tation cassette (pC-neerGc, pT-neerGc) consistently gave
higher expression than the forward orientation cassette
(pC-cGreen, pT-cGreen) (Figure 3A, C). The reason for
this is unknown but presumably reflects a more favorable
context for CMV-driven expression proximal the 3' LTR
compared to near the packaging sequence (Ψ).
Conclusion
In this report we demonstrate how in vitro-transcribed ret-
roviral RNA genomes can be utilized to transfer a high-
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systems. Using this cassette we observe an increase in
expression level of up to 3.5 times in primary human cells,
reflecting the provision of an intron and the use of strong
enhancer/promoter and polyadenylation signals. The
ability to circumvent packaging cell transcription, post-
transcriptional editing and translation of the vector
genome, while maintaining assembly into virions, effec-
tively addresses the shortcomings of current retroviral sys-
tems. Thus, this approach is based on standard molecular
biology techniques, yet allows virtually any genetic
sequence constellation to be manifested by the integrated
retroviral provirus: Strong enhancers/promoters, introns
and polyadenylation signals for boosting gene expression;
gene reporters that encompass multiple exon-introns;
post-transcriptional signal sequences to improve gene
trapping; cytotoxic gene expression or shRNA expression
cassettes that target essential genes.
Production of retroviruses by conventional packaging cell transcription or in vitro transcribed genomesFigure 1
Production of retroviruses by conventional packaging cell transcription or in vitro transcribed genomes. A) Ret-
roviruses are produced by transfecting vector plasmids into a packaging cell line (e.g. 293T-based Phoenix cells) that expresses 
requisite viral structural proteins. Cis-sequences in the LTR promote transcription and editing of the retroviral RNA genome 
which is then exported to the cytoplasm for assembly into a viral particle. Mature virions bud from the surface and can infect 
target cells. B) If an intron is embedded in the retroviral sequence it is removed by the nuclear splicing prior to packaging, such 
that the packaged retroviral genome lacks the intron. C) A retroviral vector incorporating an additional polyadenylation signal 
(pA) will yield an unproductive truncated viral genome. D) A new approach is to synthesize the retroviral gen
omic transcript in vitro and transfect it into the packaging cell cytoplasm where it is directly packaged into a virus particle. In the 
pT system vector, the promoter/enhancer (U3) sequence in the 5'LTR is replaced with the promoter sequence for bacteri-
ophage T7 RNA polymerase, enabling in vitro transcription of the retroviral genomic RNA. Avoidance of nuclear functions 
allows packaging of retroviral RNA incorporating various editing signals (introns and polyadenylation signals) and subsequent 
transfer into target cells.Page 3 of 6
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Vectors
Vectors pT-cGreen/neerGc (L311/L312) were based on
vector L139 pT7RU5mcsSIN, a derivative of LB-G [9] in
which the GFP has been removed and the 3'LTR replaced
with a self-inactivating 3'LTR (SIN) from the vector pTra
[2]. L139 thus carries in the following order: A T7 site
fused to the transcriptional start site of the MMLV RU5
region of the LTR, an extended packaging sequence (Ψ), a
multiple cloning site and a self-inactivating 3'LTR fol-
lowed by forty A residues. Vectors pC-cGreen/neerGc
(L309/L310) were based on vector L060 pCRU5
Puro2Amcs, a derivative of p96.7 [12]. This vector carries
a composite CMV promoter fused to the transcriptional
start site of the MMLV RU5 region of the LTR, an extended
packaging sequence (Ψ), multiple cloning site and 3'LTR.
Vector pCI (Promega) contains a CMV promoter, an opti-
mized chimeric intron and an SV40 polyadenylation site
selected to drive strong constitutive expression [10]. A T7
polymerase initiation site within the expression cassette of
pCI was removed by deleting the sequence between the
unique NheI site (filled) and the ScaI site 22 bp upstream
(pCIdeltaT7). An EcoRI/NotI fragment from pCGFP [13]
encompassing the GFP coding sequence was then cloned
into the corresponding sites of pCIdeltaT7. The complete
CMV-intron-GFP-SV40pA cassette was excised with BglII
and ClaI, blunt ended and cloned into L060 (XhoI, EcoRI,
blunted) and L139 (PmeI). Both orientations of insert
were obtained, producing pT-cGreen/neerGc and pC-
cGreen/neerGc.
Genomic RNA production
To generate the uncapped retroviral genomic transcripts,
MluI-linearized pT-vector DNA was transcribed with T7
polymerase (MEGAscript, Ambion, Austin, TX). RNA was
quantified (ND-1000 spectrophotometer, NanoDrop
Technologies, Wilmington, DE) and the quality checked
by denaturing agarose gel electrophoresis [14] (data not
shown).
Transfection and retroviral transduction
Standard retroviral vectors (pC) were transfected into 293-
based Phoenix A packaging cells by the standard protocol
[12,15] which for pC-GFP typically produces titers of
around 1 × 107 gfu/ml for infection of primary human
endothelial cells.
The in vitro transcribed genomic RNA was introduced into
the packaging cells using the cationic lipid DMRIE-C (Inv-
itrogen, San Diego, CA). The RNA was mixed with lipid at
Schematics of the retroviral vectorsFigure 2
Schematics of the retroviral vectors. Standard retroviral vectors were based on the pC-GFP vector [12]. pC-cGreen and 
pC-neerGc, carry an additional optimized GFP expression cassette comprising the CMV immediate early promoter, a chimeric 
intron and SV40 late pA, in opposite orientations. The pT-GFP vector has a T7RU5 composite 5'-LTR and modified 3'LTR 
where the U5 region has been replaced by a poly-A tract for in vitro transcription of vector genomic RNA [9]. pT-cGreen and 
pT-neerGc each contain a CMV expression cassette as above.Page 4 of 6
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of 250 μl of serum-free OptiMEM (Invitrogen, San Diego,
CA) and incubated at room temperature for 20 minutes.
Subconfluent (80%) Phoenix-A packaging cells in poly-
lysine coated 12-well plates were prepared by rinsing with
serum-free medium and 360 μl OptiMEM was added per
well. The RNA-lipid mixture was added dropwise to the
cells and incubated for 2 hours before the cells were
washed and incubated in complete medium. pT virus-
containing medium (1 ml) was harvested 18 hours later.
Titers were typically approximately 1 × 105 gfu/ml for
infection of primary human endothelial cells [9].
A) Packaging cell expressionFigure 3
A) Packaging cell expression. Packaging cells were transfected with equal amounts of pC-GFP, pC-cGreen and pC-neerGc 
retroviral vector plasmids. GFP expression was quantified in single cells at 24 hours by flow cytometry. B) Expression levels 
in infected cells. At 18 hours post-transfection, conditioned medium was harvested from the packaging cells and used to 
infect human umbilical vein cells (HUVEC). GFP expression was quantified in single cells at 48 hours post-infection by flow 
cytometry. pC-GFP infected cells expresses strong GFP levels, while neither the pC-cGreen nor the pC-neerGc retroviral vec-
tor produced detectable viral infection. ND: none detected. C) A high expression retroviral vector using in vitro tran-
scribed genomes. Early passage primary endothelial cells (HUVEC) were infected for 24 hours using serial dilutions of virus 
generated by the pC-GFP, pT-GFP, pT-cGreen and pT-neerGc vectors. The GFP expression level of individual cells harboring 
single viral integrations was measured by flow cytometry at 48 hours post-infection. GFP expression in the proviruses driven 
by the optimized CMV promoter/intron/pA cassette (pT-cGreen, pT-neerGc) is substantially higher than that obtained by LTR-
promoter dependent expression (pC-GFP, pT-GFP).
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Primary human umbilical vein endothelial cells (HUVEC,
passage 1–3; Cambrex, Rockland, ME) were cultured
according to the supplier's recommendations. Cells were
infected as described (e.g. plated at 40,000/12-well; 5 μg/
ml protamine sulfate) [15]. Viral supernatants were
diluted in medium to obtain a multiplicity-of-infection
yielding 10–20% GFP-positive cells corresponding to sin-
gle viral infections. Typical dilutions used were 1/100
(pC-GFP) or 1/3–1/9 (pT vectors). GFP expression meas-
urements were performed on a FACSCalibur cytometer
(Becton Dickinson, San Jose, CA) and analysis was carried
out using Flowjo [16].
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